Generate Biomedicines (GENB)
Builds protein therapeutics through a closed-loop generative-biology platform.
Something off on this page? Send us feedback.
Develops protein therapeutics using a platform that combines computation, experiments, and scalable biohardware. The clinical-stage company also works through collaborations with Amgen and Novartis.
Protein therapeutics are designed through a closed-loop platform that connects computation, experiments, and scalable biohardware. The company describes the process as generating, building, measuring, and learning from therapeutic proteins.
Founded by Flagship Pioneering and launched in 2020, the clinical-stage biotechnology company is developing programmable biology rather than pursuing a conventional single-asset model. Gevorg Grigoryan, co-founder and CTO, leads development of the Generate Platform.
Machine learning, high-throughput experimentation, and at-scale structural determination underpin the platform. A CryoEM laboratory in Andover supports structural work in that loop.
Collaborations with Amgen and Novartis form part of the operating context. The business depends on translating its integrated platform into therapeutic programs and executing across computational and laboratory systems.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 28, 2026 | H.C. Wainwright | Reiterate | Buy | $25 | $30 |
| May 14, 2026 | Morgan Stanley | Reiterate | Overweight | $22 | |
| May 8, 2026 | H.C. Wainwright | Target | $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $457.4M · Total debt $62.6M · Total assets $561.7M · Shareholders' equity $456.0M
- Revenue
- $6.3M
- Operating income
- −$71.6M
- Net income
- −$67.3M
No dividends on record.
| Institutions58 holders · as of Mar 31, 2026 | 72.41% | 92.82M shares | |
| Otherremainder | 27.59% | 35.37M shares |
128.19M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Flagship Pioneering Inc.Institution | 48.89% | 62.67M | 13Fas of Mar 31, 2026 |
FMR LLCInstitution | 3.29% | 4.22M | 13Fas of Mar 31, 2026 |
Capital World InvestorsInstitution | 3.12% | 4.00M | 13Fas of Mar 31, 2026 |
Braidwell LPInstitution | 2.80% | 3.59M | 13Fas of Mar 31, 2026 |
JPMorgan Chase & CoInstitution | 2.30% | 2.95M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Absci
Generative AI and wet-lab platform for protein biologics
- AbCellera Biologics
Technology platform for discovering and developing antibody medicines
- Recursion Pharmaceuticals
AI-native platform for end-to-end drug discovery and development
- Schrödinger
Physics-based computational platform for molecular discovery
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Generate Biomedicines | $16.16 | −0.65% | $2.09B | — | — | 154.2 | — |
| Absci | $8.82 | +0.23% | $1.49B | — | — | 955.0 | −49.4% |
| AbCellera Biologics | $11.27 | −0.80% | $3.47B | — | — | 52.4 | −76.3% |
| Recursion Pharmaceuticals | $3.39 | +0.41% | $1.77B | — | — | 32.3 | −61.8% |
| Schrödinger | $20.74 | −0.68% | $1.56B | — | — | 6.0 | +7.5% |
| Median | — | — | 42.4 | −55.6% |